EA201892443A1 - Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови - Google Patents

Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Info

Publication number
EA201892443A1
EA201892443A1 EA201892443A EA201892443A EA201892443A1 EA 201892443 A1 EA201892443 A1 EA 201892443A1 EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A1 EA201892443 A1 EA 201892443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood cells
antibodies against
pharmaceutical compositions
clinical use
against antigen
Prior art date
Application number
EA201892443A
Other languages
English (en)
Russian (ru)
Inventor
Марк Р. Х. Кребс
Дэвид Дай
Шантану Сьюл
Даниа Рабах
Дэвид Мартин
Original Assignee
Байоджен Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Ма Инк. filed Critical Байоджен Ма Инк.
Publication of EA201892443A1 publication Critical patent/EA201892443A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201892443A 2016-04-28 2017-04-27 Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови EA201892443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
EA201892443A1 true EA201892443A1 (ru) 2019-04-30

Family

ID=58672794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892443A EA201892443A1 (ru) 2016-04-28 2017-04-27 Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Country Status (14)

Country Link
US (2) US20190284281A1 (https=)
EP (1) EP3448425A1 (https=)
JP (3) JP7045327B2 (https=)
KR (5) KR20240159012A (https=)
CN (2) CN109475623B (https=)
AU (2) AU2017258191B2 (https=)
CA (1) CA3022116A1 (https=)
CO (1) CO2018012506A2 (https=)
EA (1) EA201892443A1 (https=)
IL (2) IL262514B2 (https=)
MA (1) MA44763A (https=)
MX (3) MX2018012945A (https=)
PH (1) PH12018502278A1 (https=)
WO (1) WO2017189827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
AU2021391803A1 (en) * 2020-12-03 2023-07-06 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
JP2026502000A (ja) * 2022-12-28 2026-01-20 デュアリティ・バイオロジクス（シャンハイ）カンパニー・リミテッド 抗ｂｄｃａ２抗体－薬物コンジュゲートおよびその使用
AU2024348487A1 (en) * 2023-09-28 2026-04-23 Nanjing Leads Biolabs Co., Ltd. Bdca2 monoclonal antibody, fusion protein composed of same and taci, and method and use therefor
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
AU2013359419B2 (en) * 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Also Published As

Publication number Publication date
NZ747504A (en) 2025-08-29
JP2024038308A (ja) 2024-03-19
MX2025000037A (es) 2025-02-10
CA3022116A1 (en) 2017-11-02
AU2017258191A1 (en) 2018-11-15
IL262514B1 (en) 2025-08-01
AU2024203240A1 (en) 2024-06-13
KR20220028150A (ko) 2022-03-08
JP2022084782A (ja) 2022-06-07
IL262514A (en) 2018-12-31
WO2017189827A1 (en) 2017-11-02
JP7045327B2 (ja) 2022-03-31
KR20190002563A (ko) 2019-01-08
KR20240159012A (ko) 2024-11-05
AU2017258191B2 (en) 2024-06-13
JP2019520316A (ja) 2019-07-18
BR112018072125A2 (pt) 2019-03-19
KR102366547B1 (ko) 2022-02-23
CN116850282A (zh) 2023-10-10
US20190284281A1 (en) 2019-09-19
CN109475623A (zh) 2019-03-15
IL262514B2 (en) 2025-12-01
NZ787392A (en) 2025-08-29
CO2018012506A2 (es) 2018-12-14
PH12018502278A1 (en) 2019-09-09
MX2018012945A (es) 2019-03-06
IL321561A (en) 2025-08-01
KR20250088784A (ko) 2025-06-17
EP3448425A1 (en) 2019-03-06
US20250289895A1 (en) 2025-09-18
MX2023008075A (es) 2023-07-18
KR20240033168A (ko) 2024-03-12
CN109475623B (zh) 2023-05-26
MA44763A (fr) 2019-03-06

Similar Documents

Publication Publication Date Title
EA201892443A1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
JOP20220225B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201890006A1 (ru) Применение экзосом для лечения болезни
EP4406554A3 (en) Anti-cd3 antibody formulations
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790239A1 (ru) Молекула-носитель для антигенов
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201791067A1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
EA202090063A1 (ru) Композиции и способы для лечения таупатий
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos